Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An FDA advisory committee voted 6-2 to recommend approval of Kynapid vernakalant IV to treat acute
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury